This report deliverables include a Pdf report and an Excel-based forecast model and covers the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Canada). The base year of the sales forecast model is 2024, and the forecast period is 2024-2034. This report also includes a number of recent enhancement to the forecast models, specifically the US LoA analysis tab and the interactive patient flow tab. The patient flow tab helps to summarize the number of patients treated on each class of therapy for each year of the forecast period for the 7MM.
The analyst estimates that throughout the forecast period (2024-2034), 12-month diagnosed prevalent cases of cystic fibrosis (CF) are anticipated to increase in the 7MM, across all age-groups. Treatment rates will also increase because of roll-out of more newborn screening and genetic testing programs, improved life expectancy of patients, and anticipated increase in treatment options with the launch of novel CFTR modulators and pipeline agents. The CF pipeline in the 7MM remains limited with most of the pipeline targeting the CFTR, suggesting a shift from symptom management to disease targeting. The CF market is expected to grow from $11.1 billion in 2024 to $16.0 billion by 2034 at a compound annual growth rate (CAGR) of 3.8% across the 7MM.
The analyst estimates that throughout the forecast period (2024-2034), 12-month diagnosed prevalent cases of cystic fibrosis (CF) are anticipated to increase in the 7MM, across all age-groups. Treatment rates will also increase because of roll-out of more newborn screening and genetic testing programs, improved life expectancy of patients, and anticipated increase in treatment options with the launch of novel CFTR modulators and pipeline agents. The CF pipeline in the 7MM remains limited with most of the pipeline targeting the CFTR, suggesting a shift from symptom management to disease targeting. The CF market is expected to grow from $11.1 billion in 2024 to $16.0 billion by 2034 at a compound annual growth rate (CAGR) of 3.8% across the 7MM.
Scope
- Overview of cystic fibrosis (CF) - including epidemiology, disease etiology and management.
- Topline CF drugs market revenue, annual cost of therapy, and anticipated sales for late-stage pipeline drugs.
- Key topics covered include assessment of marketed therapies and pipeline agents, unmet needs, pipeline assessment and market outlook for the US, 5EU, and Canada over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the seven-market CF therapeutics market. Insightful review of the key industry drivers and barriers.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the seven-market cystic fibrosis (CF) therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seven-market CF market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the seven-market CF therapeutics market from 2024-2034.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1. Preface
3. Disease Overview
4. Epidemiology
5. Current Treatment Options
6. Patient Flow
7. Unmet Needs and Opportunities
8. R&D Strategies
9. Pipeline Assessment
10. Market Outlook
11. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Vertex Pharmaceuticals
- Roche
- Merck
- Verona Pharma
- 4D Molecular Therapeutics
- BiomX
- Novabiotics
- Enterprise Therapeutics
- Spirovant Sciences
- Boehringer Ingelheim
- Armata Pharmaceuticals
- Arna Pharma
